Historical position

Renaissance Technologies LLC’s Pacira Biosciences Inc (PCRX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Renaissance Technologies LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2014Earliest verified positive filing snapshot
Latest statusHistorical positionBased on the latest supported relationship state
Peak shares2.85MHighest verified quarter-end share count
Quarters reported26Verified quarters with shares above zero
What happened?

Renaissance Technologies LLC first reported Pacira Biosciences Inc in Q2 2014. The reported position was increased and reduced across later filings. Verified positive position history runs through Q4 2025. The current relationship status cannot be determined reliably from supported data.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2025
Sold 11.9% of the position−254.20K shares · 1.88M shares remained
Filing context

Quarter-end price $25.88

Q3 2025
Sold 10.7% of the position−257.40K shares · 2.14M shares remained
Filing context

Quarter-end price $25.77

Q2 2025
Bought 6.9% more+155.00K shares · 2.40M shares reported after the change
Filing context

Quarter-end price $23.90

Q1 2025
Bought 12.4% more+248.00K shares · 2.24M shares reported after the change
Filing context

Quarter-end price $24.85

Q3 2024
Sold 4.2% of the position−87.20K shares · 1.98M shares remained
Filing context

Quarter-end price $15.05

Q2 2024
Bought 9.8% more+184.00K shares · 2.07M shares reported after the change
Filing context

Quarter-end price $28.61

Portfolio importance

How important was Pacira Biosciences Inc in Renaissance Technologies LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.1%Q4 2025
Last reported rank#307Rank unavailable
Peak portfolio weight0.2%Q1 2021
Best historical rank#90Q1 2021
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$24.692026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$25.88Q4 2025

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Renaissance’s secret models, complete trading book, exact trade dates or execution prices.